Russia's economic problems make it more dependent on China
The ex-Microsoft CEO starts anew as owner of the Los Angeles Clippers, the NBA's most expensive team
What happens in the next seven days will tell us a lot about the potential risk to workers who treated Thomas Eric Duncan
Paul Budnitz is the founder of Ello, the new anti-ad, pro-porn social network for all your most pretentious friends
Defined-contribution plans aren't living up to their promise
A new book surveys the best places to hide out from the digital world
TV programmers rush to the Internet as more and more Americans are starting to watch some, if not all, of their TV shows online
The company did not sign an accord to enforce stricter labor rules in Bangladesh by a deadline set by the school
Small businesses are changing hands at the fastest pace since the recession
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."